Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Sirturo
Bedaquiline is a diarylquinoline antibiotic specifically developed for the treatment of multi-drug resistant tuberculosis (MDR-TB). It inhibits mycobacterial ATP synthase, an enzyme essential for energy production in Mycobacterium tuberculosis, thus disrupting bacterial replication. Bedaquiline is typically used in combination with other anti-TB drugs as part of a longer treatment regimen.
For the treatment of multi-drug resistant tuberculosis (MDR-TB) in adults.
Increased risk of death and QT interval prolongation. Bedaquiline should be used only in combination with other drugs for the treatment of multi-drug resistant tuberculosis when an effective treatment regimen cannot otherwise be provided. Bedaquiline should not be used for latent TB infection or for treatment of drug-susceptible TB.
Outcome:
Increased risk of QT prolongation
Mechanism:
Both drugs prolong the QT interval.
Outcome:
Decreased bedaquiline levels
Mechanism:
Rifampin induces CYP3A4, which metabolizes bedaquiline.
Outcome:
Potential for drug interaction
Mechanism:
Both drugs are metabolized by CYP3A4.
Most likely new formulation: Liposomal bedaquiline for improved delivery and reduced toxicity (2025, 60% confidence)
Based on usage patterns and emerging resistance, there is a 70% likelihood of increased restrictions on bedaquiline use in the next 5 years.
Antibiotic, Diarylquinoline
Diarylquinoline